{"id":"NCT00548691","sponsor":"American Regent, Inc.","briefTitle":"Safety and Tolerability of FCM vs Standard of Care in Treating Iron Deficiency Anemia in Chronic Kidney Disease Patients","officialTitle":"A Multi-center, Randomized Controlled Study to Investigate the Safety and Tolerability of IV Ferric Carboxymaltose (FCM) vs Standard Medical Care in Treating Iron Deficiency Anemia in Chronic Kidney Disease Patients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-10","primaryCompletion":"2009-01","completion":"2009-07","firstPosted":"2007-10-24","resultsPosted":"2015-05-13","lastUpdate":"2018-02-20"},"enrollment":513,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Anemia"],"interventions":[{"type":"DRUG","name":"Ferric Carboxymaltose","otherNames":[]},{"type":"DRUG","name":"Standard Medical Care (SMC)","otherNames":[]}],"arms":[{"label":"Ferric Carboxymaltose (FCM)","type":"EXPERIMENTAL"},{"label":"Standard Medical Care (SMC)","type":"ACTIVE_COMPARATOR"}],"summary":"The Objective of this study is to study the safety of FCM in patients with anemia caused by chronic kidney failure","primaryOutcome":{"measure":"Incidence of Treatment-emergent Serious Adverse Events (SAE's)","timeFrame":"from Day 0 through 30 days after the last dose of study drug","effectByArm":[{"arm":"Ferric Carboxymaltose (FCM)","deltaMin":11,"sd":null},{"arm":"Standard Medical Care (SMC)","deltaMin":36,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":10},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":254},"commonTop":[]}}